Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.66 |
| ▸ | CTSL | P07711 | 6/20 | 0.66 |
| ▸ | CTSS | P25774 | 6/20 | 0.66 |
| ▸ | CTSB | P07858 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643093 | 1.00 | CTSK (0.66) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL1059174 | 1.00 | CTSK (0.66) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL31397623 | 0.88 | CTSL (0.58) | CTSKCTSLCTSSCTSBALDH1A1 | |
| SCHEMBL6782182 | 0.87 | CTSK (0.70) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL5192015 | 0.87 | CTSK (0.70) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL6311475 | 0.87 | CTSK (0.70) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL8823948 | 0.87 | CTSK (0.65) | CTSKCTSLCTSSCTSB | |
| SCHEMBL28979566 | 0.87 | CTSL (0.67) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL22952873 | 0.87 | CTSL (0.67) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL2228722 | 0.87 | CTSL (0.67) | CTSKCTSLCTSSCTSBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115960003-A | Synthesis method of meta-hydroxylamine bitartrate | 中科苏州药物研究院 | 2023-04-14 | — | — | CN | claimed |
| CN-115960003-A | Synthesis method of meta-hydroxylamine bitartrate | 中科苏州药物研究院 | 2023-04-14 | — | — | CN | disclosed |
| US-8030359-B2 | Polymer formulations of CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2011-10-04 | — | — | US | disclosed |
| US-7863307-B2 | Process for synthesizing a CETP inhibitor | MERCK SHARP & DOHME LLC | 2011-01-04 | — | — | US | disclosed |
| US-20100227903-A1 | Polymer Formulations of CETP Inhibitors | MERCK & CO., INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-20100041724-A1 | Process For Synthesizing A CETP Inhibitor | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
| WO-2007118963-A2 | SUBSTITUTED N-(PHENETHYL)BENZAMIDE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-10-25 | — | — | WO | disclosed |
| WO-2007118964-A1 | SUBSTITUTED N-(PHENETHYL)BENZAMIDE DERIVATIVES, PREPARATION AND USES THEREOF | GENFIT (FR) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227903-A1 | Polymer Formulations of CETP Inhibitors | CETP, PCSK9, APOB | CTSK 1078/4885CTSL 1322/4885CTSS 942/4885 |
| US-20100041724-A1 | Process For Synthesizing A CETP Inhibitor | CETP, MTTP, CTDSP1 | CTSK 295/4885CTSL 285/4885CTSS 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.